Search Results - "Gómez, HL"

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer by Martín, M, Barrios, CH, Torrecillas, L, Ruiz-Borrego, M, Bines, J, Segalla, J, Ruiz, A, García-Sáenz, JA, Torres, R, de la Haba, J, García, E, Gómez, HL, Llombart, A, Rodríguez de la Borbolla, M, Baena, JM, Barnadas, A, Calvo, L, Pérez-Michel, L, Ramos, M, Castellanos, J, Rodríguez-Lescure, A, Cárdenas, J, Vinholes, J, Martínez de Dueñas, E, Godes, MJ, Seguí, MA, Antón, A, López-Álvarez, P, Moncayo, J, Amorim, G, Villar, E, Reyes, S, Sampaio, C, Cardemil, B, Escudero, MJ, Bezares, S, Carrasco, E, Lluch, A

“…Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts)…”
Get full text

Abstract P6-07-20: Variables measured at Central Nervous System (CNS) relapse, but not Immunophenotype, identify groups of breast cancer patients with shorter post CNS-relapse survival by Gómez, HL, Pinto, JA, Schwarz, JL, Vigil, CE, Vallejos, CS

“…Objective: We evaluated breast cancer immunophenotype and variables measured at CNS-relapse as prognostic factors in a cohort of Hispanic patients. Methods: We…”
Get full text

Abstract P6-06-41: Non-palpable tumor is a surrogate factor for longer disease free survival in early breast cancer: Evaluation of a 23 years-Venezuelan cohort by Contreras, AC, Acosta, V, Torres, LG, Ferri, N, López, H, Marin, E, Juan, P, Gil, ME, Pinto, JA, Flores, CF, Gómez, HL

“…INTRODUCTION: Tumor size has long been recognized as the strongest predictor of the outcome of patients with breast cancer. While screening programs are…”
Get full text

Preoperative serum albumin as a predictor of complications following total hip replacement in patients with rheumatoid arthritis by Haro-Gómez, H L, Merida-Herrera, E, Torres-Fernández, B J, Pérez-Hernández, E, Torres-González, R, Pérez-Atanasio, J M

“…Rheumatoid arthritis is a chronic inflammatory disease characterized by polyarthritis with progressive articular wear, immunologic abnormalities and increasing…”
Get more information

Abstract P4-09-18: Triple Negative Breast (TNBC) Cancer in Hispanic Population: Clinicopathological and Recurrence Features by Gómez, HL, Velarde, RG, Neciosup, SP, Cruz, WR, Mas, LA, Suazo, JF, Pinto, JA, Vigil, CE, Vallejos, CS

“…Background: TNBC is characterized by the lack of hormonal receptors and HER2 expression and occurs most frequently in Black and Hispanic than in Caucasian…”
Get full text

Abstract P4-09-11: Variables of Worse Outcome in Premenopausal ≥35 Years old Patients (pts) by Vallejos, CS, Gómez, HL, Cotrina, JM, Marcelo, MJ, Doimi, FF, Neciosup, SP, Suazo, JF, Pinto, JA, Velarde, RG, Vigil, CE

“…Background: Breast cancer (BC) has a worse prognosis in young than in older women; there is a lack of a standard definition of ages included in definition of…”
Get full text

Abstract P1-14-02: Different Outcomes in Breast Cancer (BC) Patients with CNS Metastases According to IHC Phenotype by Gómez, HL, Vigil, CE, Cruz, WR, Neciosup, SP, Pinto, JA, Suazo, JF, Mas, LA, Doimi, FF, Falla, MJ, Vallejos, CS

“…Background: Phenotype plays an important role in BC biology and outcome. We evaluated the characteristics and outcomes of clinical stages I-III BC patients…”
Get full text

Abstract P6-09-11: Ki67 cut offs and oncotype DX recurrence score in early breast cancer by Namuche, F, Ruiz, R, Flores, C, Gomez, HL, Aguilar, A

“…Background: The gene expression profiling assay OncotypeDx (ODX) predicts the likelihood of estrogen receptor (ER) positive breast cancer (BC) recurrence and…”
Get full text

Abstract P1-06-12: Optimizing the use of oncotype Dx in early breast cancer by Ruiz, R, Namuche, F, Flores, C, Aguilar, A, Gomez, HL

“…Background: Oncotype Dx (ODX) prognosticates the risk of recurrence and predicts the benefit of adjuvant chemotherapy in estrogen-receptor-positive breast…”
Get full text

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update by Loibl, Sibylle, Jassem, Jacek, Sonnenblick, Amir, Parlier, Damien, Winer, Eric, Bergh, Jonas, Gelber, Richard D, Restuccia, Eleonora, Im, Young-Hyuck, Huang, Chiun-Sheng, Dalenc, Florence, Calvo, Isabel, Procter, Marion, Caballero, Carmela, Clark, Emma, Raimbault, Alice, McConnell, Robin, Monturus, Estefania, de Azambuja, Evandro, Gomez, Henry L, Bliss, Judith, Viale, Giuseppe, Bines, Jose, Piccart, Martine

“…JCO The APHINITY trial (ClinicalTrials.gov identifier: NCT01358877) previously demonstrated that pertuzumab added to adjuvant trastuzumab and chemotherapy…”
Get full text

Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 by Colleoni, Marco, Gray, Kathryn P, Gelber, Shari, Láng, István, Thürlimann, Beat, Gianni, Lorenzo, Abdi, Ehtesham A, Gomez, Henry L, Linderholm, Barbro K, Puglisi, Fabio, Tondini, Carlo, Kralidis, Elena, Eniu, Alexandru, Cagossi, Katia, Rauch, Daniel, Chirgwin, Jacquie, Gelber, Richard D, Regan, Meredith M, Coates, Alan S, Price, Karen N, Viale, Giuseppe, Goldhirsch, Aron

“…To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse…”
Get full text

Abstract P1-07-18: Breast cancer in young patients, twelve years of experience in a single institution by Morante, ZD, Pacheco, C, Limón, RS, Neciosup, S, Gomez, HL

“…Breast cancer is very rare in young women and has a more aggressive biological behavior and a worse prognosis than in older premenopausal women. This study was…”
Get full text

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer by Baselga, J., Manikhas, A., Cortés, J., Llombart, A., Roman, L., Semiglazov, V.F., Byakhov, M., Lokanatha, D., Forenza, S., Goldfarb, R.H., Matera, J., Azarnia, N., Hudis, C.A., Rozencweig, M.

“…Nonpegylated liposomal doxorubicin liposomal doxorubicin, (Myocet™; Sopherion Therapeutics, Inc Canada, and Cephalon, Europe) (NPLD; Myocet®) in combination…”
Get full text

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer by Baselga, José, Zamagni, Claudio, Gómez, Patricia, Bermejo, Begoña, Nagai, Shigenori E., Melichar, Bohuslav, Chan, Arlene, Mángel, Lászlo, Bergh, Jonas, Costa, Frederico, Gómez, Henry L., Gradishar, William J., Hudis, Clifford A., Rapoport, Bernardo L., Roché, Henri, Maeda, Patricia, Huang, Liping, Meinhardt, Gerold, Zhang, Joshua, Schwartzberg, Lee S.

“…A previous randomized phase II trial suggested that sorafenib might enhance the efficacy of capecitabine in patients with metastatic breast cancer. However, in…”
Get full text

Abstract P5-09-08: Molecular evaluation of Peruvian patients with hereditary breast cancer reveals a novel germline mutation in BRCA1 by Ponce, J, Vigil, C, Araujo, JM, Castañeda, C, Calderon, G, Buleje, JL, Acosta, O, Danos, P, Huaman, F, Guevara-Fujita, ML, Aguilar, A, Pinto, JA, Gomez, HL, Fujita, R

“…Background Breast cancer is the leading cancer in women worldwide, while in Peru is the second most frequent cancer with a high incidence of triple negative…”
Get full text

Abstract GS4-02: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials by Pagani, O, Regan, MM, Fleming, GF, Walley, BA, Colleoni, M, Láng, I, Gomez, HL, Tondini, C, Burstein, HJ, Goetz, MP, Ciruelos, EM, Stearns, V, Debled, M, Martino, S, Geyer, CE, Pinotti, G, Coates, AS, Goldhirsch, A, Gelber, RD, Francis, PA

“…Background: The combined results of TEXT and SOFT, after 5.7 years median follow-up, found adjuvant E+OFS significantly improved disease-free survival (DFS) vs…”
Get full text

Abstract P5-23-02: Quality of life (QoL) in male breast cancer (BC): Prospective study of the EORTC10085/TBCRC029/BIG2-07/NABCG International male BC program by Schroder, C, Cardoso, F, Dijkstra, N, van Leeuwen-Stok, E, Linderholm, B, Morgenstern, D, Van Poznak, C, Wolff, AC, Poncet, C, Gomez, HL, Aalders, K, Bjelic-Radisic, V, Werutsky, G, Tryfonidis, K, Coens, C, Giordano, SH, Ruddy, KJ

“…Introduction: Male BC is a rare disease (dx) for which management is extrapolated from trials in female BC. Comprehensive prospective data about QoL in men…”
Get full text

Abstract P5-18-01: Extended continuous vs intermittent adjuvant letrozole in postmenopausal women with lymph node-positive, early breast cancer (IBCSG 37-05/BIG 1-07 SOLE): Impact on patient-reported symptoms and quality of life by Ribi, K, Luo, W, Colleoni, M, Karlsson, P, Chirgwin, J, Aebi, S, Jerusalem, G, Neven, P, Di Lauro, V, Gomez, HL, Ruhstaller, T, Abdi, E, Di Leo, A, Müller, B, Maibach, R, Gelber, RD, Goldhirsch, A, Coates, AS, Regan, MM, Bernhard, J

“…Background: SOLE efficacy results presented at ASCO 2017 showed that extended intermittent vs continuous letrozole for 5 years did not improve disease-free…”
Get full text

Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial by Albain, K, Gray, RJ, Sparano, JA, Makower, DF, Pritchard, KI, Hayes, DF, Geyer, CE, Dees, EC, Goetz, MP, Olson, JA, Lively, T, Badve, SS, Saphner, TJ, Wagner, LI, Whelan, TJ, Ellis, MJ, Paik, S, Wood, WC, Ravdin, PM, Keane, MM, Gomez, HL, Reddy, PS, Goggins, TF, Mayer, IA, Brufsky, AM, Toppmeyer, DL, Kaklamani, VG, Berenberg, JL, Abrams, J, Sledge, GW

“…Background: Black race is associated with worse outcomes in localized hormone receptor (HR)-positive breast cancer in population-based and in clinical trial…”
Get full text

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial by Ribi, Karin, Luo, Weixiu, Colleoni, Marco, Karlsson, Per, Chirgwin, Jacquie, Aebi, Stefan, Jerusalem, Guy, Neven, Patrick, Di Lauro, Vincenzo, Gomez, Henry L., Ruhstaller, Thomas, Abdi, Ehtesham, Biganzoli, Laura, Müller, Bettina, Barbeaux, Annelore, Graas, Marie-Pascale, Rabaglio, Manuela, Francis, Prudence A., Foukakis, Theodoros, Pagani, Olivia, Graiff, Claudio, Vorobiof, Daniel, Maibach, Rudolf, Di Leo, Angelo, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Regan, Meredith M., Bernhard, Jürg

“…Background In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in…”
Get full text